Cai Qi, Secretary of the Beijing Municipal Party Committee, investigated InnoCare Pharmaceutical Co., Ltd.
On the morning of April 7, 2020, Beijing Municipal Party Committee Secretary Cai Qi and his delegation came to Beijing InnoCare Pharmaceutical Co., Ltd. for investigation. Dr. Cui Jisong, co-founder, chairman and CEO of InnoCare Pharmaceutical Co., Ltd., and Dr. Zhao Renbin, executive director of biological and clinical development strategy, received the investigation.
(Picture source "Zhizheng" public account)
Dr. Cui Jisong reported to Secretary Cai Qi a series of scientific and technological innovation achievements achieved by InnoCare Pharmaceutical Co., Ltd. in less than 5 years, and that InnoCare Pharmaceutical Co., Ltd., as the first biomedical technology stock in 2020, had its first "cloud roadshow and cloud gong" on the Hong Kong Stock Exchange. The listing situation focused on the innovative drug Orelabrutinib, which is currently undergoing priority approval by the State Food and Drug Administration, and also put forward some suggestions for the development of Beijing's biomedical industry. It is hoped that Beijing will support innovative drugs represented by InnoCare Pharmaceutical Co., Ltd. Orelabrutinib in the construction of MAH system and subsequent production supervision and management, help innovative pharmaceutical companies represented by InnoCare Pharmaceutical Co., Ltd. to further develop and expand, and improve the competitiveness of Beijing's innovative pharmaceutical companies.
Later, accompanied by Dr. Cui Jisong and Dr. Zhao Renbin, Secretary Cai Qi walked into the laboratory to learn about the progress of R&D and production.
Secretary Cai Qi urged InnoCare Pharmaceutical Co., Ltd. to continue to strengthen scientific research, produce more original results and major breakthroughs, and strive to be the best biopharmaceutical company. Local governments and relevant departments should provide services and policies to help solve practical problems and allow companies to develop with peace of mind.
InnoCare Pharmaceutical Co., Ltd. has fully resumed work since February 10, and corporate operations and project development are actively advancing. Since the resumption of work, there have been frequent good news. The new drug application (NDA) of the company's independently developed chemical Class 1 new drug orelabrutinib (ICP-022) for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) was accepted by the China National Medical Products Administration (NMPA) in March 2020 and included in the priority review. In the same month, InnoCare Pharmaceutical Co., Ltd.'s ICP-723 IND application was also accepted. In addition, during the COVID-19 epidemic, InnoCare Pharmaceutical Co., Ltd., in addition to fully coordinating and arranging prevention and control measures and strengthening its own supervision to ensure the safety of employees when they return to work, also actively donated money and assisted in purchasing medical supplies to donate to hospitals, contributing to the fight against the epidemic.
Beijing leaders Cui Shuqiang and Sui Zhenjiang participated in the inspection and investigation.